These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 34715821)

  • 41. Ambroxol as a novel disease-modifying treatment for Parkinson's disease dementia: protocol for a single-centre, randomized, double-blind, placebo-controlled trial.
    Silveira CRA; MacKinley J; Coleman K; Li Z; Finger E; Bartha R; Morrow SA; Wells J; Borrie M; Tirona RG; Rupar CA; Zou G; Hegele RA; Mahuran D; MacDonald P; Jenkins ME; Jog M; Pasternak SH
    BMC Neurol; 2019 Feb; 19(1):20. PubMed ID: 30738426
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cholinesterase inhibitors for dementia with Lewy bodies.
    Wild R; Pettit T; Burns A
    Cochrane Database Syst Rev; 2003; 2003(3):CD003672. PubMed ID: 12917981
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermittent theta-burst stimulation combined with physical therapy as an optimal rehabilitation in Parkinson's disease: study protocol for a randomised, double-blind, controlled trial.
    Jin ZH; Wang YX; Meng DT; Qin Y; Duan YN; Fang JP; Wang RD; Liu YJ; Liu C; Wang P; Yan HJ; Zhen Y; An X; Chen KK; Yu X; Lyu D; Yan XY; Fang BY
    Trials; 2023 Jun; 24(1):410. PubMed ID: 37328845
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Azathioprine immunosuppression and disease modification in Parkinson's disease (AZA-PD): a randomised double-blind placebo-controlled phase II trial protocol.
    Greenland JC; Cutting E; Kadyan S; Bond S; Chhabra A; Williams-Gray CH
    BMJ Open; 2020 Nov; 10(11):e040527. PubMed ID: 33234645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.
    Wei Q; Tan Y; Xu P; Tao E; Lu Z; Pan X; Wang B; Liu C; Dong X; Tian Y; Sun X; Cattaneo C; Chen S; Shang H;
    CNS Drugs; 2022 Nov; 36(11):1217-1227. PubMed ID: 36346534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cholinesterase inhibitors for rarer dementias associated with neurological conditions.
    Li Y; Hai S; Zhou Y; Dong BR
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD009444. PubMed ID: 25734590
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A multicentre, randomised controlled trial to compare the clinical and cost-effectiveness of Lee Silverman Voice Treatment versus standard NHS Speech and Language Therapy versus control in Parkinson's disease: a study protocol for a randomised controlled trial.
    Sackley CM; Rick C; Au P; Brady MC; Beaton G; Burton C; Caulfield M; Dickson S; Dowling F; Hughes M; Ives N; Jowett S; Masterson-Algar P; Nicoll A; Patel S; Smith CH; Woolley R; Clarke CE;
    Trials; 2020 May; 21(1):436. PubMed ID: 32460885
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The cost-effectiveness of specialized nursing interventions for people with Parkinson's disease: the NICE-PD study protocol for a randomized controlled clinical trial.
    Radder DLM; Lennaerts HH; Vermeulen H; van Asseldonk T; Delnooz CCS; Hagen RH; Munneke M; Bloem BR; de Vries NM
    Trials; 2020 Jan; 21(1):88. PubMed ID: 31941538
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The PD-Ballet study: study protocol for a randomised controlled single-blind hybrid type 2 clinical trial evaluating the effects of ballet dancing on motor and non-motor symptoms in Parkinson's disease.
    Podlewska AM; Batzu L; Soukup T; Sevdalis N; Bakolis I; Derbyshire-Fox F; Hartley A; Healey A; Woods A; Crane N; Pariante C; Ray Chaudhuri K
    BMC Complement Med Ther; 2024 Jan; 24(1):41. PubMed ID: 38233784
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series.
    Bullock R; Cameron A
    Curr Med Res Opin; 2002; 18(5):258-64. PubMed ID: 12240787
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent transcranial direct current stimulation and progressive resistance training in Parkinson's disease: study protocol for a randomised controlled trial.
    Hendy AM; Tillman A; Rantalainen T; Muthalib M; Johnson L; Kidgell DJ; Wundersitz D; Enticott PG; Teo WP
    Trials; 2016 Jul; 17(1):326. PubMed ID: 27430304
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effects of a biomechanical-based Tai Chi program on gait and posture in people with Parkinson's disease: study protocol for a randomized controlled trial.
    Law NY; Li JX; Zhu Q; Nantel J
    Trials; 2023 Jun; 24(1):241. PubMed ID: 37386473
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
    Barone P; Poewe W; Albrecht S; Debieuvre C; Massey D; Rascol O; Tolosa E; Weintraub D
    Lancet Neurol; 2010 Jun; 9(6):573-80. PubMed ID: 20452823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rivastigmine in Parkinson's disease dementia.
    Lalli S; Albanese A
    Expert Rev Neurother; 2008 Aug; 8(8):1181-8. PubMed ID: 18671661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protocol of a randomised delayed-start double-blind placebo-controlled multi-centre trial for Levodopa in EArly Parkinson's disease: the LEAP-study.
    Verschuur CV; Suwijn SR; Post B; Dijkgraaf M; Bloem BR; van Hilten JJ; van Laar T; Tissingh G; Deuschl G; Lang AE; de Haan RJ; de Bie RM
    BMC Neurol; 2015 Nov; 15():236. PubMed ID: 26584951
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis.
    Wang HF; Yu JT; Tang SW; Jiang T; Tan CC; Meng XF; Wang C; Tan MS; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Feb; 86(2):135-43. PubMed ID: 24828899
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of Rivastigmine (Acetyl Cholinesterase Inhibitor) versus Placebo on Manic Episodes in Patients with Bipolar Disorders: Results from a Double Blind, Randomized, Placebo-Controlled Clinical Trial.
    Keshavrzi A; Rezaei H; Haghighi M; Jahangard L
    Neuropsychobiology; 2019; 78(4):200-208. PubMed ID: 31315114
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mild and marked executive dysfunction and falls in people with Parkinson's disease.
    Pelicioni PHS; Menant JC; Henderson EJ; Latt MD; Brodie MA; Lord SR
    Braz J Phys Ther; 2021; 25(4):437-443. PubMed ID: 33349526
    [TBL] [Abstract][Full Text] [Related]  

  • 59. COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of home-based, online cognitive training on cognition and brain networks in Parkinson's disease.
    van Balkom TD; Berendse HW; van der Werf YD; Twisk JWR; Zijlstra I; Hagen RH; Berk T; Vriend C; van den Heuvel OA
    BMC Neurol; 2019 Jul; 19(1):179. PubMed ID: 31366395
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Safety and efficacy of venglustat in GBA1-associated Parkinson's disease: an international, multicentre, double-blind, randomised, placebo-controlled, phase 2 trial.
    Giladi N; Alcalay RN; Cutter G; Gasser T; Gurevich T; Höglinger GU; Marek K; Pacchetti C; Schapira AHV; Scherzer CR; Simuni T; Minini P; Sardi SP; Peterschmitt MJ
    Lancet Neurol; 2023 Aug; 22(8):661-671. PubMed ID: 37479372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.